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Purpose: The in vitro antimicrobial activity of ascorbic acid derivatives against   Propionibacterium 
acnes was tested either alone or in combination with a variety of antimicrobial agents, and their 
fractional inhibitory concentration index was determined using checkerboard tests. The antimi-
crobial effectiveness of zinc ascorbate in the treatment of acne vulgaris, either alone or in com-
bination with antibiotics such as clindamycin that are commonly used in Japan for the treatment 
of acne vulgaris, was therefore examined.
Materials and methods: The antimicrobial susceptibility of 41 strains of clindamycin-sensitive 
and/or clindamycin-resistant P . acnes isolated from acne vulgaris patients was tested, in com-
parison with a type strain of P . acnes.
Results: Zinc ascorbate showed antimicrobial activity against a type strain of P . acnes and 
its concentration (0.064%) was sufficiently lower than the normal dose (5%) of other ascorbic 
acid derivatives. Combinations of zinc ascorbate with clindamycin, erythromycin, and chloram-
phenicol showed an additive effect, and zinc ascorbate alone effectively inhibited the growth 
of all P . acnes including clindamycin-resistant strains.
Conclusion: The results provide novel evidence that the combination of zinc ascorbate and 
clindamycin is effective for acne vulgaris treatment.
Keywords: antimicrobial susceptibility, ascorbic acid derivatives, combination therapy, 
checkerboard test
Introduction
Propionibacterium acnes is an anaerobic, Gram-positive skin microbe that colonizes 
sebaceous glands and pilosebaceous follicles.1 This organism is considered to play a 
principal role in the development of acne vulgaris.1 Acne vulgaris is a chronic inflam-
matory disease characterized by typical inflammatory events, including the overpro-
duction of sebum, abnormal desquamation of the sebaceous follicle epithelium, and 
P . acnes proliferation.1–3 Regarding the pathogenic factors for acne development and 
aggravation, ultraviolet irradiation and peroxidation of sebum lipids have been reported 
to activate inflammatory mediators such as reactive oxygen species.4
Ascorbic acid derivatives are some of the most widely used antioxidants for 
protecting the skin.5,6 The antioxidative effect of 5% sodium ascorbyl phosphate has 
demonstrated efficacy in acne vulgaris.7 However, it remains unclear whether ascorbic 
acid derivatives have antimicrobial activity against P . acnes.
Many topical and systemic treatments have been proposed for acne vulgaris.8 
Clindamycin and erythromycin are the most frequently used agents against P . acnes.8,9 
On the other hand, many studies have reported the emergence of P . acnes with high 
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level resistance to macrolides including clindamycin because 
long-term antibiotic therapy is commonly used to treat acne 
vulgaris.10–12 In Japan, a study conducted between 1994 and 
1995 revealed that macrolide-resistant strains were found in 
only 4% (2/50) of P . acnes isolates from patients with acne 
vulgaris. However, they were found in 10% (5/48) of P . acnes 
isolates between 2006 and 2007, showing P . acnes resistance 
to macrolides has been increasing in Japan.8,9
Macrolide resistance in P . acnes is considered to be 
caused by mutation of the peptidyl transferase region in the 
domain V of 23S rRNA, and by the target site alteration with 
the 23S rRNA dimethylase that is encoded by erm(X).13 In 
addition, these mutations is associated with cross resistance to 
clindamycin.14 Therefore, the increasing prevalence of mac-
rolide-resistant P . acnes, including clindamycin-resistant 
P . acnes, is a serious problem, because acne treatment by 
clindamycin is extremely difficult.
Recently, it has been reported that antibiotic combination 
enhances the therapeutic effect.15,16 In this study, the in vitro 
efficacy of ascorbic acid derivates against P . acnes alone and 
in combination with clindamycin, erythromycin, chloram-
phenicol, minocycline, or levofloxacine was examined.
Material and methods
Bacterial strains and drugs
A total of 41 P . acnes strains used in this study were isolated 
from patients with acne vulgaris between 2006 and 2007 in 
Japan, and four strains of these were clindamycin-resistant 
P . acnes with mutation of the peptidyl transferase region in 
the domain V of 23S rRNA gene: A2058G, or A2059G.9 The 
patients were given topical antibiotics instead of systemic 
antibiotics. The samples were cultured on modified Gifu 
anaerobic medium (GAM) agar (Nissui Pharmaceutical 
Co, Tokyo, Japan) under anaerobic conditions at 35°C for 
72 hours. P . acnes was identified by Api 20A (bioMérieux, 
Marcy I’Etoile, France).9 P . acnes JCM 6473 (ATCC 11828) 
strain was used as the quality control strain for antimicrobial 
susceptibility testing. Clindamycin, erythromycin, chloram-
phenicol, and minocycline were purchased from Sigma-
Aldrich (Tokyo, Japan). All other chemicals used were of 
the highest analytical grade.
Susceptibility tests
Susceptibility testing was performed using microbroth 
dilution methods, according to the criteria of the Japanese 
Society of Chemotherapy.17,18 The samples were cultured in 
GAM broth (Nissui Pharmaceutical Co) and adjusted to a 
McFarland standard number 1. A dilute bacterial suspension 
was used to inoculate wells of a 96-well microplate, each well 
containing a different concentration of the drug being tested. 
Double dilutions of the drugs were prepared. The concen-
trations of the drugs in the GAM broth ranged from 0.06 to 
128 µg/mL (antimicrobial agents) or 1.25 to 1280 µg/mL 
(ascorbic acid derivatives), and a final concentration of 
105 colony-forming units (CFU) of test bacteria per well 
was added to each dilution. The plates were incubated in 
an anaerobic gas-generating pouch (Anaero Pack System; 
Mitsubishi Gas Chemical Co, Tokyo, Japan) at 35°C for 
48 hours. After the positive control lacking the antimicrobial 
agent demonstrated good growth, the minimum inhibitory 
concentration (MIC) for each antibiotic was defined as the 
lowest concentration of antibiotic required to inhibit bacterial 
growth, indicated by the absence of turbidity.
Fractional inhibitory concentration  
(FIC) index
The efficacy of a combination of zinc ascorbate and antimi-
crobial agents against P . acnes was determined by checker-
board tests using microbroth dilution methods.19 Fractional 
inhibitory concentration (FIC) indices were calculated 
using the following formula: FIC index = (MIC of drug A 
in combination/MIC of drug A alone) + (MIC of drug B 
in combination/MIC of drug B alone).20 An index of ,0.5 
was considered as synergism; that ,1.0 but .0.5 as addi-
tive action; and that .2.0 as antagonism. The samples were 
adjusted to the McFarland standard number 1 and a final 
concentration of 105 CFU/well of test bacteria. The MICs 
of the combinations were determined after incubation at 
35°C for 48 hours.
Results
The antibiotic susceptibility of P. acnes  
to ascorbic acid derivatives
The antibiotic susceptibility of P . acnes JCM 6473 to ascor-
bic acid derivatives zinc ascorbate, magnesium ascorbyl 
phosphate, and sodium ascorbyl phosphate was investigated 
(Table 1). The MIC of zinc ascorbate was 640 µg/mL, whereas 
the MICs of ascorbic acid, magnesium ascorbyl phosphate, 
and sodium ascorbyl phosphate were $1280 µg/mL. The 
normal dose of ascorbic acid derivatives is 5% (50 mg/mL).7 
These results indicate that zinc ascorbate sufficiently inhibits 
the growth of P . acnes in the normal dose. Thus, zinc ascor-
bate was used in further experiments.
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Combined effect of zinc ascorbate and 
various antimicrobial agents against P. acnes
To study the antimicrobial effects of combinations of zinc 
ascorbate and antimicrobial agents such as clindamycin, 
erythromycin, chloramphenicol, minocycline, and levo-
floxacin, the FIC index was determined by checkerboard 
tests (Table 2). In combinations of zinc ascorbate with clin-
damycin, erythromycin, or chloramphenicol, the MIC of zinc 
ascorbate reduced, and the FIC indices ranged from 0.625 to 
0.75. The values exhibited an additive effect against P . acnes 
JCM 6473. Conversely, the FIC indices for the combinations 
of zinc ascorbate with minocycline or levofloxacin showed 
no effect.
Clindamycin is approved and commonly used in Japan for 
the treatment of acne vulgaris.8,9 Thus, the antimicrobial effect 
of zinc ascorbate combined with clindamycin for 37 strains 
of clindamycin-sensitive P . acnes isolated from patients with 
acne vulgaris was investigated. As shown in Table 3, the MIC 
range of zinc ascorbate was approximately twofold lower in 
combination with clindamycin compared with that of zinc 
ascorbate and clindamycin alone. The average FIC index was 
0.84, exhibiting an additive effect.
Combined effect of zinc ascorbate and 
various antimicrobial agents against 
clindamycin-resistant P. acnes isolated 
from patients with acne vulgaris
Clindamycin-resistant P . acnes with mutation of the pep-
tidyl transferase region in the domain V of 23S rRNA 
has been increasing in Japan.9 The antimicrobial effect of 
zinc ascorbate combined with clindamycin, erythromycin, 
and chloramphenicol for four strains (PA001–PA004) of 
clindamycin-resistant P . acnes with a transition of adenine 
to guanine at the position of 2058 (A2058G: PA001–PA003) 
or 2059 (A2059G: PA004) was investigated. As shown in 
Table 4, zinc ascorbate was equally effective at inhibiting 
the growth of clindamycin-resistant P . acnes strains (MIC 
640 μg/mL). In combinations of zinc ascorbate with clin-
damycin, erythromycin, and chloramphenicol, the MIC of 
zinc ascorbate reduced (MIC range: 160–320 µg/mL). In 
addition, the FIC index of PA004 strain with clindamycin-
resistant P . acnes was 0.75, exhibiting an additive effect.
Discussion
In the microbroth dilution methods, according to the criteria 
of the Japanese Society of Chemotherapy, a twofold serial 
dilution series is used to determine the effectiveness of the 
test drug, with 1 µg/mL as the primary dilution.17,18 In this 
study, the concentrations of the drugs ranged from 0.06 to 
128 µg/mL. However, ascorbic acid derivatives showed no 
effect in this concentration. It was confirmed that MIC of 
zinc was 1280 µg/mL (data not shown), which is similar 
to that reported by Fluhr et al.21 Therefore, the concen-
trations of ascorbic acid derivatives ranged from 1.25 to 
1280 µg/mL.
Five percent of sodium ascorbyl phosphate has been 
reported to reduce acne lesions by 20.14% and 48.82% 
within 4 and 8 weeks, respectively.7 In addition, topical 
(1.2%) and systemic (30 mg) zinc have been reported to 
show efficacy in the treatment of acne vulgaris.21,22 In the 
present study, the MIC (640 µg/mL) of zinc ascorbate 
against P . acnes JCM 6473 corresponded to 0.064%, and 
the MIC value was lower than other ascorbic acid deriva-
tives (MIC $1280 µg/mL). Although further experiments 
are needed to examine the drug kinetics and the stability of 
zinc ascorbate, it is expected that the calculating concen-
tration of zinc ascorbate would be 2800 µg/mL when it is 
applied on the skin (4 mg/cm2) as an external preparation.23 
These results suggest a possibility that zinc ascorbate (MIC 
Table 1 Susceptibility of Propionibacterium acnes JCM 6473 to 
ascorbic acid derivatives
Ascorbic acid derivates MIC
Ascorbic acid $1280
Zinc ascorbate 640
Magnesium ascorbyl phosphate $1280
Sodium ascorbyl phosphate $1280
Abbreviation: MIC, minimum inhibitory concentration (µg/mL).
Table 2 Combined effects of zinc ascorbate and antimicrobial 
agents against Propionibacterium acnes JCM 6473
Drug MIC (FIC index) Interaction
Zinc ascorbate 640
Clindamycin 0.03
Erythromycin 0.13
Chlorlamphenicol 2
Minocycline 0.25
Levofloxacin 0.5
Zinc ascorbate/Clindamycin 80/0.02 (0.63) Additive
Zinc ascorbate/Erythromycin 160/0.06 (0.75) Additive
Zinc ascorbate/Chloramphenicol 160/1 (0.75) Additive
Zinc ascorbate/Minocycline 640/0.25 (2) Antagonism
Zinc ascorbate/Levofloxacin 640/0.5 (2) Antagonism
Note: The interaction was defined as synergistic if the FIC index was ,0.5, additive 
if the FIC index was between 0.5 and 1.0, antagonistic if the FIC index $2. 
Abbreviations: MIC, minimum inhibitory concentration (µg/mL); FIC, fractional 
inhibitory concentration.
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Table 3 Combined effect of zinc ascorbate and clindamycin against 37 strains of Propionibacterium acnes isolated from patients with 
acne vulgaris
Drug MIC ranges (MIC90) FIC Interaction
Alone Combined Range Average
Clindamycin 0.13–2 
(2)
0.06–1 
(1)
0.63–1 0.84 Additive
Zinc ascorbate 160–640 
(640)
80–320 
(160)
Abbreviations: MIC, minimum inhibitory concentration (µg/mL); FIC, fractional inhibitory concentration; MIC90, concentration of drugs which inhibited growth in 90% of 
the strains tested.
Table 4 Combined effect of zinc ascorbate and antimicrobial agents against four strains of macrolides-resistant Propionibacterium acnes 
isolated from patients with acne vulgaris
Strain 
no.
MIC (FIC index)
AZn CLDM EM CP AZn/CLDM AZn/EM AZn/CP
PA001 640 $128 $128 2 160/$128 
(NC)
160/$128 
(NC)
320/1 
(1)
PA002 640 $128 $128 2 320/$128 
(NC)
320/$128 
(NC)
320/1 
(1)
PA003 640 $128 $128 1 320/$128 
(NC)
160/$128 
(NC)
160/0.5 
(0.75)
PA004 640 64 $128 1 160/32 
(0.75)
320/$128 
(NC)
160/0.5 
(0.75)
Abbreviations: MIC, minimum inhibitory concentration (µg/mL); FIC, fractional inhibitory concentration; PA, Propionibacterium acnes; AZn, zinc ascorbate; CLDM, clindamycin; 
EM, erythromycin; CP, chloramphenicol; NC, not calculated.
640 µg/mL) sufficiently inhibits the growth of P . acnes in 
the concentration that is lower than the normal dose of other 
ascorbic acid derivatives and zinc.
Choi et al24 reported that the antimicrobial mechanism 
involves the capability of zinc ions to inhibit glycolysis of 
microorganisms by oxidizing thiol groups in essential gly-
colytic enzymes, therefore, the antimicrobial mechanism 
of zinc ascorbate may be similar to that of zinc. However, 
a combined effect of zinc ascorbate and minocycline or 
levofloxacin was not proved. Clindamycin, erythromycin, 
and chloramphenicol inhibit the protein synthesis of bacteria 
by binding to the 50S subunit of the bacterial ribosome.25 In 
contrast, the binding sites of minocycline and levofloxacin 
are on the 30S subunit of the ribosome and on DNA topoi-
somerase IV , respectively.26,27 Thus, the difference in anti-
bacterial mechanism may be related to the combined effect 
of each of these. In addition, it is possible that minocycline 
and levofloxacin chelate with metal ions, including zinc,28,29 
resulting in reduced antimicrobial activity. Further experi-
ments are needed to clarify the mechanism of zinc ascorbate 
against P . acnes.
Macrolides are used not only as antimicrobial agents but 
also as anti-inflammatory agents, and are the most commonly 
used to treat acne vulgaris.9 Clindamycin shows a similar 
effect to macrolides and is the most popular topical antibacte-
rial for acne vulgaris in Japan. However, clindamycin-resistant 
P . acnes strains have been increasing in Japan.8,9 An increase 
of clindamycin-resistant P . acnes including macrolides and 
an epidemic of the multiple-drug-resistant P . acnes can 
be expected in the future. It is reported that combination 
therapy with antimicrobial agents and other agents such as 
the external retinoids and benzoyl peroxide is effective in 
preventing the emergence of the antibiotic-resistant strains 
of P . acnes.15,16 In the present study, it was found that zinc 
ascorbate inhibited the growth of the clindamycin-resistant 
P . acnes strains (MIC 640 µg/mL). In addition, although the 
FIC of zinc ascorbate in combination with clindamycin was 
unable to be calculated because the MIC of clindamycin 
alone and in combination was $128 µg/mL (3/4 strains), 
it reduced the MIC of zinc ascorbate against all strains. 
Moreover, the FIC index of PA004 strain with clindamycin-
resistant P . acnes was 0.75, exhibiting an additive effect. 
These results strongly suggest that the combination of zinc 
ascorbate and clindamycin will be useful for preventing the 
emergence of clindamycin-resistant P . acnes and for treating 
acne vulgaris.
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Conclusion
The results of this study provide novel evidence that zinc 
ascorbate inhibits the growth of P . acnes, and its concentration 
(0.064%) is sufficiently lower than the normal dose (5%) of 
other ascorbic acid derivatives. In addition, zinc ascorbate 
shows an additive antimicrobial effect in vitro in combina-
tion with clindamycin, erythromycin, and chloramphenicol 
against clindamycin-sensitive and/or clindamycin-resistant 
P . acnes. These findings may provide novel insights into 
acne therapy. Recently, combination therapy with benzoyl 
peroxide and clindamycin has become common worldwide. 
Further experiments are needed to compare zinc ascorbate 
plus clindamycin and benzyol peroxide plus clindamycin.
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